Vildagliptin: the known and unknown
Vildagliptin is an innovative, effective DPP-4 inhibitor to be used as mono- or combination therapy of type 2 diabetes. The drug consistently reduces the level of glycated hemoglobin and does not increase the risk of hypoglycemia and cardiovascular disease. Numerous clinical studies have demonstrate...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2016-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/66 |